[The efficacy of human NGF dipeptide mimetic on the streptozotocin-induced model of diabetes in rats].

The effect of a new dimeric dipeptide mimetic GK-2 of the loop-4 human NGF (hexamethylendiamide-bis-N-monosuccinyl-glycil-L-lysine) was investigated for the first time on the dynamics of hyperglycemia and body weight loss caused in Wistar rats by streptozotocin (45 mg/kg i.p.) Prophylactic (2 weeks before streptozotocin) daily administration combined with therapeutic (4 weeks after STZ) administration of GK-2 (0.1 mg/kg i.p.) was shown to attenuate significantly the degree of hyperglycemia and to reverse the streptozotocin-induced weight loss.